Prior to joining Bantam, Dr. Luther was most recently the Senior Vice President and Chief Scientific Officer for Albany Molecular Research (AMRI). In this role, he was responsible for AMRI’s global discovery and development businesses. Before AMRI, Michael was the Corporate Vice President of Global Discovery Research for Charles River Laboratories.
Dr. Luther has spent 25 years in the bio-pharmaceutical industry, including serving as the Vice President and Site Head at the Merck-Frosst Centre for Therapeutic Research in Montreal. In this role, he led drug discovery to proof of concept efforts for Inflammation and Metabolic Disease. Dr. Luther was also with GlaxoSmithKline for over 16 years in a number of positions of increasing responsibility including his last role as a Vice President in Discovery Research. In his various roles at GSK, he was responsible for leading several successful discovery teams that led to launch of new medicines as well as leading some of the pharmaceutical industry’s initial efforts in both personalized/precision medicine and drug repositioning.
Dr. Luther holds Bachelor of Science degrees in Biology and Chemistry from North Carolina State University, a doctorate degree in Biochemistry from the St. Louis University School of Medicine, and an MBA from Duke University. He is the author of over 45 scientific publications, and holds issued patents in diagnostics and pharmaceutical discovery and development.
Dr. Luther was one of the founding board members for both the College of Life Sciences Research Foundation at North Carolina State University, and the Quebec Drug Discovery Consortium. He is a board member at Transgenomic Inc. In addition, he is on the board of directors for The Chagas Disease Foundation, Albany College of Pharmacy and Health Sciences, and the North Carolina Biotechnology Industry Organization.
Dr. Cooper holds a PhD in Chemistry from Rutgers University and is the author of over 100 publications and patents and patent applications. At present, Dr. Cooper is principal at Cooper MedChem Consulting, LLC. He is also an adjunct professor at Montclair State University teaching medicinal and organic chemistry.
Dr. Cooper is an ACS Fellow and very active within the American Chemical Society. He is presently a national councilor for the last 20 years representing the North Jersey Section and is a past chair of that Section. He has served on numerous committees nationally, regionally and locally and is presently serving on the Committee on Committees (ConC) which is one of three council elected committees. He has also served on a number of ACS Presidential Task forces.
Dr. Andy Anantha, Head of CMC, is the President of AVA Pharma Consultants and has over 30 years of experience in successfully conducting research and development in bio-pharmaceutical organizations and companies in the CMC space for both NCEs and Generics.
Prior to AVA Pharma Consultants, Dr. Anantha was most recently the Vice President of Pharmaceutical Development & Quality at vTv Therapeutics. In this role, he was responsible for complete CMC development and regulatory filings. Several lead candidates were taken to IND, Phase 1, 2 and Phase 3 stage. Before vTv Therapeutics, Dr. Anantha was the General Manager of Research at Torrent Pharma, India on both NCE and ANDA fronts. Responsibilities included API, formulation and Analytical development activities and Regulatory filings. Dr. Anantha has spent 30 years in the bio-pharmaceutical industry, including serving as a Manager/Principal Scientist at Wyeth Research for 9 and 1/2 years. of In this role, in addition to research and development in Analytical and Quality, he led interdisciplinary team of scientists on projects from CMC side. Other experience includes 7 years in the Generics research and development area at G & W labs.
Dr. Anantha is an author of several peer reviewed publications and was a secretary and is a member at the API manufacturing division of American Association of Pharmaceutical Sciences.